Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM

NCT07588256 is registered in ClinicalTrials.gov with New Taipei City Medical Association as lead sponsor.

NCT NCT07588256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07588256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
New Taipei City 888 Digital Medical AI Platform for the Prevention and Treatment of the Three Highs (Hypertension, Hyperglycemia, Hyperlipidemia) and Cardio-Renal-Vascular Diseases: Validation and Implementation Through Large-Scale Cluster Randomized Clinical Trials: T-888-DIGICARE-DREAM
Lead sponsor
New Taipei City Medical Association
Phase
Not applicable
Overall status
Recruiting
Start date
February 5, 2026
Completion date
February 5, 2029
Enrollment
4,162 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease prevention, cardiovascular disease risk factor, digital medicine, hyperglycaemia (diabetic), hyperlipidemia, hypertension, microalbuminuria, microalbuminuria /creatinine ratios acr